2019 China Pharmaceutical Logistics Development Report
report directory
Chapter 1 my country’s medical and pharmaceutical policies and their influence. 1
Section 1 Institutional reform of the State Council reflects the determination to deepen medical reform 2
Section 2 The coverage of medical insurance continues to increase, and the medical insurance bureau “stable, accurate and ruthless” to promote the key work of medical reform5
The third section of the new version of the “National Essential Medicines List” expands capacity and strengthens drug treatment attributes 22
Section 4 Reforms in the field of drug supervision promote the improvement of China’s drug quality and innovation environment 27
Section 5 “Two-vote system” is fully implemented, and the effect is gradually emerging. 31
Section 6 The application of Internet technology in the medical and health field has been consolidated and developed. 35
Section 7 Pharmacy classification and grading further promote the outflow of prescription drugs. 37
Section 8 Multi-department coordination to promote the construction of drug traceability system 41
Chapter 2 Status and Trend of China’s Pharmaceutical Industry. 44
Section 1 Analysis of the development of medical terminals in my country. 45
Section 2 Analysis of the Development Status of my country’s Pharmaceutical Industry. 51
Section 3 Analysis of the Current Situation of Pharmaceutical Business in my country. 64
Section 4 Development of Chinese Pharmaceutical Parks. 69
Section 5 Analysis of the development pattern of my country’s pharmaceutical industry. 75
Section 6 Development Trend of my country’s Pharmaceutical Industry. 82
Chapter 3 Current Situation of my country’s Pharmaceutical Logistics Development 92
The first section of my country’s pharmaceutical logistics scale. 93
Section 2 Status Quo and Trend of Informatization and Automation in my country’s Pharmaceutical Logistics Field 99
Section 3 Development Status of Third-Party Pharmaceutical Logistics in my country. 107
The fourth section of the current situation and development of hot pharmaceutical logistics 115
Section 5 Development Prospects of my country’s Pharmaceutical Logistics Industry 127
Chapter 4 Hot Areas of Pharmaceutical Logistics. 130
The first section of China’s pharmaceutical logistics standardization development status. 131
The second section of my country’s pharmaceutical reverse logistics development status 137
Section 3 Professional Pharmacy Development Model and Practice. 139
Section 4 Application of Blockchain in Pharmaceutical Supply Chain Finance. 145
Section 5 Analysis of Pharmaceutical Logistics Talents 150
Section 6 Development Status of Foreign Hotspot Pharmaceutical Circulation and Logistics Industry 157
Chapter 5 Excellent practice cases in the field of pharmaceutical logistics in my country. 173
The first one-stop B2B trading platform of Runyao Mall. 173
The second section of Shanghai Pharmaceutical Logistics Center Co., Ltd.’s national temperature-controlled transportation under the “two-invoice system”. 177
The third section of KingMed Medical Group’s county-level medical community biological sample logistics service. 180
The fourth section of Shanghai Kangzhan Logistics Co., Ltd. Pharmaceutical Division Pharmaceutical Cold Chain Information System Upgrade Innovation Achievement. 186
The fifth section is about the practice of Shandong Lanjian Logistics Technology Co., Ltd. about the construction of the central logistics center of Nanjing Pharmaceutical Kangjie Logistics Co., Ltd. 192
Section 6 Shengshi Chinese Supply Chain Management Co., Ltd. cooperates with Carrier Transportation Refrigeration (China) to use CPS to unlock a new model of third-party service 200
Section 7 Dometic Group Vehicle Active Refrigeration Cold Chain Transport Box. 204
Section 8 Shanghai Kejian Software Technology Co., Ltd. builds “Smart Harbin Medicine” 209
Section 9 WMS of Shanghai Fuller Information Technology Company’s multi-mode, multi-format, group-type pharmaceutical enterprise
Foreword to the report
Currently, China is the world’s second largest economy and the world’s second largest pharmaceutical market. The year 2019 marks the 70th anniversary of the founding of the People’s Republic of China, and it is also a critical year for building a moderately prosperous society in an all-round way. As an important part of a well-off society, pharmaceutical logistics is facing new opportunities and new challenges with the sustained and rapid economic development.
The traditional extensive growth of pharmaceutical logistics can no longer meet the requirements of the people for high quality, high standards, high safety and high security. Industry changes are accelerating, and industrial structure adjustment will become the keynote for a period of time in the future. With the merger and reorganization among enterprises, the gradual improvement of infrastructure network, the update and iteration of science and technology, and the rapid development of new communication technology, pharmaceutical logistics has gradually become a new economic growth point and force point.
China Federation of Logistics and Purchasing Federation Pharmaceutical Logistics Branch (hereinafter referred to as “China Federation of Logistics and Pharmaceutical Logistics Branch”), with the support of relevant departments, with the active participation of vice presidents, executive directors and directors, expert committees and the majority of member units, the annual Continue to carry out enterprise research, industry research, standard formulation and revision and other work, and now collect the best parts into a book, dedicated to readers who care about and support enterprises and institutions in my country’s pharmaceutical logistics industry and other related institutions.
The “China Pharmaceutical Logistics Development Report (2019)” mainly reflects the development, existing problems and future trends of my country’s pharmaceutical logistics industry from 2018 to 2019. The report is divided into six chapters: The first chapter is China’s medical and pharmaceutical policies and their impact, focusing on the institutional reform of the State Council, the establishment of the National Medical Insurance Administration (hereinafter referred to as the “National Medical Insurance Administration”), and the full implementation of the “two-vote system”; The second chapter is the status quo and trend of China’s pharmaceutical industry, mainly introducing the status, pattern and development trend of China’s medical terminals, pharmaceutical industry, pharmaceutical business, and pharmaceutical parks; the third chapter is the development status of China’s pharmaceutical logistics, mainly introducing China’s pharmaceutical logistics industry The basic situation of development, including scale, informatization and automation level, third-party logistics, basic situation of hotspots; Chapter 4 is the hotspots of pharmaceutical logistics, mainly sorting out the hotspots of pharmaceutical logistics, including pharmaceutical logistics standardization, pharmaceutical reverse logistics, professional The application of pharmacy and blockchain technology in pharmaceutical supply chain finance, etc.; Chapter 5 is an excellent case of practice in the field of pharmaceutical logistics in China, including Runyao Mall, Shanghai Pharmaceutical Logistics Center Co., Ltd., Jinyu Medical Group County Medical Community Biology Sample logistics services, etc.; Chapter 6 is an appendix to this report, which includes key policies in the field of pharmaceutical circulation, and statistical data such as total pharmaceutical sales in 2017 without subdivisions.
As the most common pharmaceutical logistics annual report on the market, this report will continue to be published along with the development of the pharmaceutical logistics industry. The many regrets left by the lack of experience and level in the process of writing this report will be the direction for the future improvement and improvement of this report, and I sincerely hope that readers will provide valuable opinions and suggestions.
Featured Content
On July 10, 2007, the State Council issued the “Guiding Opinions of the State Council on Carrying out the Pilot Program of Basic Medical Insurance for Urban Residents”, which started the pilot work of basic medical insurance for urban residents in my country, and the medical insurance officially began to cover the urban non-employment population. In 2009, the Central Committee of the Communist Party of China and the State Council issued the “Opinions of the Central Committee of the Communist Party of China and the State Council on Deepening the Reform of the Medical and Health System”, which proposed to comprehensively roll out the basic medical insurance system for urban residents and formally establish the basic medical insurance system for urban residents. So far, my country’s new basic medical insurance system is basically sound, and the system has achieved full coverage.
In 2016, the State Council issued the “Opinions on Integrating the Basic Medical Insurance System for Urban and Rural Residents”, proposing to integrate the two systems of urban residents’ medical insurance and the new rural cooperative medical system, and to establish a unified urban and rural residents’ basic medical insurance system. As shown in Figure 1-2, as of the end of 2018, the number of people covered by basic medical insurance in my country reached 1.344 billion, and the coverage was stable at over 95%.
Chart: Number of Participants in China’s Medical Insurance from 2005 to 2018
As can be seen from Figures 1-3, the gradual improvement of China’s medical insurance system is an important reason for the development of China’s pharmaceutical industry. In 2003, the new rural cooperative medical system was implemented. By 2007, the number of participants in the new rural cooperative medical system increased by 316 million to 726 million. In 2007, the urban residents’ medical insurance system began to be implemented. The administration of the two systems has boosted the rapid growth of China’s medical insurance (including NRCMS) expenditures. In 2008, the highest year-on-year growth rate of medical insurance expenditure exceeded 40%. And this stage is the stage of rapid growth of China’s pharmaceutical industry. The high-speed and extensive growth of the pharmaceutical industry has led to frequent problems in the production and circulation of the industry and inflated prices, laying a hidden danger for the subsequent development of the pharmaceutical industry.
Figure 1-3 Comparison of my country’s medical insurance income and expenditure and the development of the pharmaceutical industry from 2006 to 2017
Before the establishment of the National Medical Insurance Bureau, my country has carried out two explorations of medical insurance negotiation. In May 2016, the results of the first medical insurance negotiation conducted by 16 departments led by the National Health and Family Planning Commission were announced. 5 products were shortlisted, and 3 were successfully negotiated, namely tenofovir disoproxil for the first-line treatment of chronic hepatitis B and targeted non-small cell lung cancer. The treatment drugs icotinib and gefitinib. The prices of the three medicines all fell by more than 50%. In June 2017, the Ministry of Human Resources and Social Security organized the second medical insurance negotiation, 44 drugs were shortlisted, and 33 were successfully negotiated, with an average drop of 37%. Medicare negotiation has greatly facilitated the use of related drugs. Taking the first batch of domestically-made Class 1.1 new drug icotinib as an example, its sales volume increased by 31% and 47% in 2016 and 2017, respectively, as shown in Figure 1-4 and Figure 1-5. The second successful medical insurance negotiation products have a relatively large sales growth, such as the domestic 1.1 class new drug Chidamide increased by more than 40 times in the third quarter of 2017.
Figure 1-4 Changes in the sales volume of icotinine from 2015 to 2018
As shown in Table 1-4, 22 products are listed in the 2018 edition of the National Essential Drugs List, and the specific criteria are: first, the drug standards have been replaced; second, the national drug regulatory authority has withdrawn its drug approval documents; third, Adverse reactions occur, and after evaluation, it is no longer suitable to be used as a national essential drug.
Figure 1-10 Distribution of Western Medicines in the 2018 National Essential Medicines List
As can be seen from Figure 2-2, from 2015 to 2017, although the growth of total health expenditures has slowed down, it still maintains a high growth rate, which is higher than the growth rate of GDP (gross domestic product) in the same period. In 2017, the total national health expenditure reached 5,159.89 billion yuan, a year-on-year increase of 11.3%. The total health expenditure as a percentage of GDP was 6.36%, an increase of 0.13 percentage points compared with the previous year.
Figure 2-2 my country’s total health expenditure and year-on-year growth rate from 2006 to 2017
The PDF version of this report has been shared with the knowledge planet of this site. Welcome to join in the review and exchange. The original website annual VIP contact “dongxizhiku” WeChat can join for free.
This article is reprinted from: https://www.dx2025.com/archives/19837.html
This site is for inclusion only, and the copyright belongs to the original author.